Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis.

Barraco, F; Greil, R; Herbrecht, R; Schmidt, B; Reiter, A; Willenbacher, W; Rayma-kers, R; Liersch, R; Wroclawska, M; Pack, R; Burock, K; Karumanchi, D; Gisslinger, H. Br J Haematol. 2020 Jun 24. doi: 10.1111/bjh.16729. Online ahead of print.

The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.

Dubsky, PC; Singer, CF; Egle, D; Wette, V; Petru, E; Balic, M; Pichler, A; Greil, R; Petzer, AL; Bago-Horvath, Z; Fesl, C; Meek, SM; Kronenwett, R; Rudas, M; Gnant, M; Filipits, M. Eur J Cancer . 2020 Jul;134:99-106. doi: 10.1016/j.ejca.2020.04.020. Epub 2020 Jun 2.

CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity.

Gutjahr, JC; Bayer, E; Yu, X; Laufer, JM; Höpner, JP; Tesanovic, S; Härzschel, A; Auer, G; Rieß, T; Salmhofer, A; Szenes, E; Haslauer, T; Durand-Onayli, V; Ramspa-cher, A; Pennisi, SP; Artinger, M; Zaborsky, N; Chigaev, A; Aberger, F; Neureiter, D; Pleyer, L; Legler, DF; Orian-Rousseau, V; Greil, R; Hartmann, TN. Haematologica. 2020 Jul 2;haematol.2019.231944. doi: 10.3324/haematol.2019.231944. Online ahead of print.

Dysphagia in the Context of a Serious Systemic Disease.

Ferstl, FS; Gampenrieder, SP; Renneberg, F; Roesch, S. Dysphagia. 2020 Jul 22. doi: 10.1007/s00455-020-10155-6. Online ahead of print.

Structure-Guided Identification of Black Cohosh (Actaea racemosa) Tri-terpenoids with In Vitro Activity against Multiple Myeloma.

Johrer, K; Stuppner, H; Greil, R; Cicek, SS. Molecules. 2020 Feb 11;25(4):766. doi: 10.3390/molecules25040766.

Structure-Guided Identification of Black Cohosh (Actaea racemosa) Triterpenoids with In Vitro Activity against Multiple Myeloma.

Johrer, K; Stuppner, H; Greil, R; Cicek, SS. Molecules. 2020 Feb 11;25(4):766. doi: 10.3390/molecules25040766.

IDO in MDS/AML disease progression and its role in resistance to azaci-tidine: a potential new drug target?

Leisch, M; Greil, R; Pleyer, L. Br J Haematol. 2020 Aug;190(3):314-317. doi: 10.1111/bjh.16710. E-pub 2020 May 17.

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib mainte-nance therapy and comparison to the general population.

Ludwig, H; Ponisch, W; Knop, S; Egle, A; Hinke, A; Schreder, M; Lechner, D; Hajek, R; Gunsilius, E; Petzer, A; Weisel, K; Niederwieser, D; Einsele, H; Willenbacher, W; Rum-pold, H; Pour, L; Jelinek, T; Krenosz, KJ; Meckl, A; Nolte, S; Melchardt, T; Greil, R; Zojer, N. Leuk Lymphoma. 2020 Feb;61(2):377-386. doi: 10.1080/10428194.2019.1666381. E-pub 2019 Sep 26.

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

Murthy, RK; Loi, S; Okines, A; Paplomata, E; Hamilton, E; Hurvitz, SA; Lin, NU; Bor-ges, V; Abramson, V; Anders, C; Bedard, PL; Oliveira, M; Jakobsen, E; Bachelot, T; Shachar, SS; Müller, V; Braga, S; Duhoux, FP; Greil, R; Cameron, D; Carey, LA; Curigliano, G; Gelmon, K; Hortobagyi, G; Krop, I; Loibl, S; Pegram, M; Slamon, D; Pa-lanca-Wessels, MC; Walker, L; Feng, W; Winer, EP. N Engl J Med. 2020 Feb 13;382(7):597-609. doi: 10.1056/NEJMoa1914609. Epub 2019 Dec 11.

Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer.

Hufnagl, C; Leisch, M; Weiss, L; Melchardt, T; Moik, M; Asslaber, D; Roland, G; Steininger, P; Meissnitzer, T; Neureiter, D; Greil, R; Egle, A. Oncol Lett. 2020 Feb;19(2):1551-1558. doi: 10.3892/ol.2019.11192. Epub 2019 Dec 9.